Multiple Myeloma Market: Market Size & Forecast 2026

Multiple myeloma is a type of blood cancer characterized by the uncontrolled growth of plasma cells in the bone marrow, leading to bone damage, anemia, kidney dysfunction, and compromised immune function. The global market includes pharmacological therapies used for newly diagnosed, relapsed, and refractory cases across hospital, specialty clinic, and home care settings. With an estimated market size of $27.21 billion in 2025, the sector continues to expand as the global burden of the disease rises.

• •Multiple myeloma is the second most common blood cancer after non-Hodgkin lymphoma
• •The 7MM (US, EU5, Japan) market alone was valued at approximately $21.3 billion in 2023
• •Market value is projected to reach over $32.51 billion by 2031-2035 depending on the forecast model

The market's growth is propelled by the rising global incidence of multiple myeloma, driven by aging demographics and improved diagnostic capabilities. Advances in treatment, particularly the introduction of novel agents such as monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies, are expanding patient access to more effective and longer-lasting regimens. Healthcare infrastructure improvements in emerging markets and growing reimbursement coverage for expensive biologics also support market expansion.

• •Rising aging population and improved diagnostic screening are increasing the prevalent patient pool
• •New drug approvals and combination therapies are driving treatment adoption rates higher
• •Ongoing clinical trials in immunotherapy and targeted agents are expected to further propel market growth

The market is segmented primarily by drug class, including proteasome inhibitors (such as bortezomib and carfilzomib), immunomodulatory drugs (such as lenalidomide and pomalidomide), monoclonal antibodies, and emerging CAR-T cell therapies. By region, North America holds the largest market share, driven by high disease prevalence, advanced healthcare infrastructure, and early adoption of novel therapies. Europe and Asia-Pacific follow, with the Asia-Pacific region expected to grow at a faster rate due to improving access to oncology care.

• •North America accounts for the largest regional share, led by the United States
• •Europe, particularly the UK, Germany, France, Italy, and Spain, represents a significant portion of the 7MM market
• •Asia-Pacific is emerging as a high-growth region driven by increasing healthcare spending and rising disease awareness

What are the recent trends and outlook?

The future of the multiple myeloma market is shaped by the rapid development of immunotherapies, including bispecific antibodies, CAR-T cell therapies, and antibody-drug conjugates, which are expected to transform the standard of care in coming years. Personalized medicine approaches and biomarker-driven treatment selection are gaining traction, supported by companion diagnostics and real-world evidence frameworks. Mergers, acquisitions, and strategic collaborations among pharmaceutical firms are accelerating pipeline innovation and market consolidation.

• •Bispecific antibodies and CAR-T therapies are anticipated to capture significant market share by the early 2030s
• •Combination regimens targeting multiple disease pathways are becoming the clinical standard
• •Real-world evidence and digital health tools are increasingly integrated into treatment monitoring and clinical decision-making